INI1-negative Tumors clinical trials at UCSF
1 research study open to eligible people
INI1 negative tumors do not have the INI1 gene, which may lead to uncontrolled cancer growth. At UCSF, a clinical trial tests nivolumab and ipilimumab together in young patients to see their effect on these tumors. Researchers are evaluating if this drug pairing offers any new benefits.
Showing trials for
Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
open to eligible people ages 6 months to 40 years
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
San Francisco, California and other locations
Our lead scientists for INI1-negative Tumors research studies include Alyssa Reddy.